Skip to Content

Equagesic Dosage

Generic name: meprobamate and aspirin
Dosage form: tablets

Medically reviewed on January 15, 2019.

The usual dosage of Equagesic is one or two tablets, each tablet containing meprobamate, 200 mg, and aspirin, 325 mg, orally 3 to 4 times daily as needed for the relief of pain when tension or anxiety is present. Equagesic is not recommended for patients 12 years of age and under.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Next → Professional

More about Equagesic (aspirin / meprobamate)

Consumer resources

Equagesic (Advanced Reading)

Other brands: Micrainin

Professional resources

Equagesic (FDA)

Related treatment guides

Pain
Anxiety

Drug Status

Availability Discontinued

Pregnancy Category Not for use in pregnancy

CSA Schedule* Some potential for abuse

Approval History Drug history at FDA

Drug Class

Analgesic combinations
Skeletal muscle relaxant combinations

Related Drugs

Anxiety Xanax, Lexapro, Cymbalta, alprazolam, escitalopram, lorazepam, duloxetine, atenolol, venlafaxine, buspirone, hydroxyzine, diazepam, More...

Pain tramadol, acetaminophen, naproxen, Tylenol, oxycodone, aspirin, ibuprofen, clonidine, amitriptyline, diclofenac, hydroxyzine, More...

Equagesic Rating

No reviews - Add your review

Equagesic Images

Pill Imprint WYETH 91 (Equagesic 325 mg / 200 mg)

Equagesic 325 mg / 200 mg (WYETH 91)

Get Email Updates

Subscribe to free Drugs.com newsletters.

By clicking Subscribe, I agree to the Drugs.com Terms & Conditions and Privacy Policy and understand that I may opt out of Drugs.com subscriptions at any time.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 Mar 2019), Cerner Multum™ (updated 1 Mar 2019), Wolters Kluwer™ (updated 28 Feb 2019) and others. Refer to our editorial policy for content sources and attributions.